ISPOR 6TH ASIA-PACIFIC CONFERENCE

6-9 September 2014 • Beijing, China

PROGRAM & SCHEDULE OF EVENTS
SATURDAY, 6 SEPTEMBER

8:00AM-12:00PM  PRE-CONFERENCE MORNING SHORT COURSES  Short Course Registration Required

1:00PM-5:00PM  PRE-CONFERENCE AFTERNOON SHORT COURSES  Short Course Registration Required

5:15PM-6:15PM  EDUCATIONAL SYMPOSIUM  Hall 3 (Level 1)

UNIVERSAL HEALTH COVERAGE: SUSTAINABLE FINANCING AND EFFICIENT DESIGN
Sponsored by Pfizer

6:30PM-7:30PM  EDUCATIONAL SYMPOSIUM  Hall 3 (Level 1)

HEPATITIS C VIRUS (HCV) DISEASE BURDEN IN ASIA (CHINA, JAPAN, SOUTH KOREA, AND TAIWAN)
Sponsored by Bristol-Myers Squibb

7:45PM-8:45PM  EDUCATIONAL SYMPOSIUM  Hall 3 (Level 1)

THINKING BEYOND COST-EFFECTIVENESS ANALYSIS: ALTERNATIVE ANALYTIC FRAMEWORKS FOR INFORMING VALUE TO STAKEHOLDERS
Sponsored by GlaxoSmithKline

9:00PM-10:30PM  WELCOME RECEPTION  Grand Ballroom (Beijing North Star Continental Grand Hotel)

All attendees welcome, no separate registration required. Please join us for a traditional performance to open the reception followed by an opportunity to network with colleagues while enjoying a drink and appetizers.
Sponsored by Merck Serono

SUNDAY, 7 SEPTEMBER

8:00AM-12:00PM  PRE-CONFERENCE SHORT COURSES  Short Course Registration Required

12:30PM-7:30PM  RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I  Hall 4 (Level 1)

1:00PM-1:25PM  WELCOME  Hall 2 (Level 2)

Chinese⇒English Interpretation
WELCOME FROM CONFERENCE CHAIR
Gordon G. Liu, PhD, ISPOR 6th Asia-Pacific Conference Chair, Professor of Economics, National School of Development (NSD), and Director, China Center for Health Economic Research (CCHER), Peking University, Beijing, China

WELCOME FROM ISPOR ASIA CONSORTIUM EXECUTIVE COMMITTEE CHAIR
Yen-Huei (Tony) Tarn, MS, PhD, 2014-2016 ISPOR Asia Consortium Executive Committee Chair and Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

WELCOME FROM ISPOR PRESIDENT
Adrian Towse, MA, MPhil, 2014-2015 ISPOR President and Director, Office of Health Economics, London, UK

1:25PM-1:45PM  OPENING SPEECH  Hall 2 (Level 2)

Chinese⇒English Interpretation
PHARMACEUTICAL POLICY, RESEARCH AND DEVELOPMENT IN CHINA
Guowei Sang, ISPOR 6th Asia-Pacific Conference Honorary Chair, President of Chinese Pharmaceutical Association (CPA), Academician of Chinese Academy of Engineering (CAE), and Vice Chairman of the Standing Committee of the 11th National People’s Congress, Beijing, China

1:45PM-3:15PM  FIRST PLENARY SESSION  Hall 2 (Level 2)

Chinese⇒English Interpretation
HEARING THE PATIENT’S VOICE IN HEALTH CARE DECISION MAKING IN ASIA

G. Liu  Y. Tarn  A. Towse

G. Sang
Health care is for the patient, but the patient’s voice is often lost in the debate among different stakeholders. This is particularly true in health care delivery and health care policy making in Asia where health care providers, payers, and producers usually dominate the discussion. Patient groups are established to amplify the patient’s voice not only at the health care delivery level, but also at the formulary and reimbursement levels. This session will discuss challenges and opportunities for how patient perspectives can be incorporated into health care decisions in Asia through the efforts of patient organizations.

Moderator: Bong-min Yang, PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

Speakers:
- Wannian Liang, PhD, Director, Department of Healthcare Reform (Office of State Council Healthcare Reform Leading Group), National Health and Family Planning Commission (NHFPC), Beijing, China
- Tao Guan, Patient and Founder, The Hemophilia Home of China, Beijing, China
- Hsiao-Yi Lin, MD, Executive Director & Chairman of Reimbursement Policy Response Committee, Taiwan Rheumatology Association, Chief Physician, Division of Allergy, Immunology & Rheumatology, Taipei Veterans General Hospital, and Associate Professor, School of Medicine, National Yang-Ming University, Taipei, Taiwan
- John Forman, Executive Director, New Zealand Organization for Rare Disorders, Thorndon, Wellington, New Zealand

4:45PM-5:15PM  ISSUE PANELS – SESSION I

CLINICAL OUTCOMES RESEARCH ISSUES

IP1: HOW TO CONSTRUCT REIMBURSEMENT SUBMISSIONS IN THE ABSENCE OF HEAD-TO-HEAD CLINICAL DATA: ITC, MTC, OR CEA?  **Hall 5B (Level 1)**

Moderator: Hansoo Kim, MSc, Market Access Manager, Bristol-Myers Squibb, Melbourne, Australia

Panelists: Danny Liew, FRACP, PhD, Professor, Medicine (RMH), The University of Melbourne, Melbourne, Australia; Stephen Goodall, MSc, PhD, Associate Professor, Center for Health Economics Research & Evaluation (CHERE), University of Technology Sydney, Sydney, Australia; Jeong Hoon Ahn, PhD, MA, Executive Director, National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP2: DISINVESTMENT IN ASIA-PACIFIC: HOW CAN THIS BE IMPLEMENTED IN HTA AND WHAT CAN BE LEARNED FROM EUROPE?  **Hall 5A (Level 1)**

Moderator: Craig Brooks-Rooney, MA, Head, Asia-Pacific, Costello Medical Singapore Pte Ltd., Singapore

Panelists: Ihaki Gutierrez-Ibarluzea, MSc, PhD, Knowledge Manager, Basque Office for Health Technology Assessment, Vitoria-Gasteiz, Spain; Isaak Kamada, MD, PhD, Professor, Health Technology Assessment and Public Policy, Graduate School of Public Policy, University of Tokyo, Tokyo, Japan; Seang Teak Tan, MSc, MBA, Chief Executive Officer, City International Hospital, Ho Chi Minh City, Vietnam

IP3: MANAGING HIGH-COST, INNOVATIVE PHARMACEUTICALS IN ASIA: IS SOMETHING LOST WHEN TRANSLATING THEORY INTO PRACTICE?  **Hall 5C (Level 1)**

Moderator: Bruce C.M. Wang, PhD, Vice President, Health Economics and Outcomes Research, Alliance Life Sciences, Somerset, NJ, USA

Panelists: Yen-Huei (Tony) Tarn, PhD, MS, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan; Adrian Towse, MA, MPhil, Director, Office of Health Economics (OHE), London, UK; Jianwei Xuan, MD, PhD, Advisory Professor, Fudan University, School of Public Health, Shanghai, China

IP4: ENVISIONING ONCOLOGY COVERAGE DECISION FRAMEWORK: HOW DO CURRENT AND FUTURE TRENDS IN ASIA-PACIFIC AFFECT THE ACCESSIBILITY?  **Room 201A/B (Level 2)**

Moderator: Jitrakul Leartsakulpanich, PhD, Director, Market Access, Asia Pacific, Johnson & Johnson Asia Pacific, Bangkok, Thailand

Panelists: Chang-Fang Chiu, MD, PhD, Vice Superintendent, Cancer Center, China Medical University Hospital, Taipei, Taiwan; Seungjin Bae, ScD, RPh, Assistant Professor, College of Pharmacy, Ewha Womans University, Seoul, South Korea; Chuen Seng Tan, MSc, Executive Officer, City International Hospital, Ho Chi Minh City, Vietnam

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES

IP5: THE PATIENT VOICE IN CHINA: WHAT IS THE WEIGHT OF PROS IN THE REIMBURSEMENT AND ACCESS DECISIONS OF PAYERS TODAY?  **Hall 4 (Level 1)**

Moderator: Andrew Worsfold, BSc, Global Therapy Area Lead, Disease Atlas, GfK, London, UK

Panelists: Lu Tong, Oncologist - Breast Cancer, Oncology, Beijing Renmin Hospital, Beijing, China; Liang Li Liang, Oncologist - Breast Cancer, Oncology, Beijing Renmin Hospital, Beijing, China; Jianwei Xuan, MD, PhD, Advisory Professor, Fudan University, School of Public Health, Shanghai, China

4:45PM-5:00PM  BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I  **Hall 4 (Level 1)**

5:00PM-6:00PM  RESEARCH PODIUM PRESENTATIONS – SESSION I

(Can be inserted here if there are any research podium presentations scheduled.)
ISPOR 6th Asia-Pacific Conference
6-9 September 2014, Beijing International Convention Center, Beijing, China

Program & Schedule of Events: Sunday, 7 September continued

5:30PM-5:45PM
PG1
CN3
Budget Impact Analysis of Crizotinib Treatment in ALK+ Non-Small-Cell Lung Cancer Patients in Thailand
Permsuwan U1, Petcharapich S2, Thongprasert S3, 1Chiang Mai University, Chiang Mai, Thailand, 2Pfizer (Thailand) Ltd., Bangkok, Thailand, Faculty of Medicine Maharaj Nakorn Chiang Mai Hospital, Meung, Thailand

5:45PM-6:00PM
PG2
CN4
Study on the Direct Medical Cost of Malignant Neoplasms Inpatients with Urban Basic Health Insurance Scheme in China
Yong M1, Xianyun J2, Jinghu L3, Zie Z2, Yunyun F1, 1Beijing University of Chinese Medicine, Beijing, China, 2China Health Insurance Research Association, Beijing, China

Diabetes Outcomes Research Studies Hall SB (Level 1)

Moderator: Fengyu Sun, MD, MSc, Director of Health Economics, Department of Corporate Affairs and Quality Control, Novo Nordisk China, Beijing, China

5:00PM-5:15PM
PG2
DB1
Impact of GLP-1RA on Heart Rate, Blood Pressure and Hypertension Among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Sun F1, Wu S2, Chai S3, Yang Z1, Yu K1, Zhan S1, 1Peking University Health Science Center, Beijing, China, 2Capital Medical University, Beijing, China, 3Tianjin Fifth Central Hospital, Tianjin, China

5:15PM-5:30PM
PG3
DB2
Efficacy and Safety of Human Insulin versus Animal Insulin Among Patients with Diabetes in China: A Meta-Analysis
Zhang HN1, Wang K1, Yang J2, Liu L3, 1China Pharmaceutical University, Nanjing, China, 2Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China

5:30PM-5:45PM
PG3
DB3
Treatment Profile and Insulin Dose as a Factor Impacting Glycemia Control Among Premix Insulin Users with T2DM in China
Liu L1, Chen Y1, Gu L1, Curtis BH2, Babineaux SM3, 1Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China, 2Eli Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, China, 3Eli Lilly and Company, Carmel, IN, USA

5:45PM-6:00PM
PG4
DB4
Clinical Characteristics Among Hypertension Patients with Dislipidemia in Shanghai, China
Xu S1, Yang H1, Wang J2, Zhao Y3, Yu F1, Xu H2, Zhang Y1, Shi Q2, Jeffers B3, Liu L1, Bureau of Health, Minhang District, Shanghai, China, 3Centers for Disease Control and Prevention, Minhang District, Shanghai, China, 4Pfizer China, Shanghai, China, 5Pfizer Inc., Peapack, NJ, USA, 6Pfizer, New York, NY, USA

Drug Use Studies Room 201AB (Level 2)

Moderator: Chee Jen Chang, PhD, Professor, Graduate Institute of Clinical Medical Sciences and Director, Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, Taiwan

5:00PM-5:15PM
PG4
DU1
Treatments Prior to and Post Percutaneous Coronary Intervention (PCI) in China
Wei M1, Sun Y1, Liu G1, Hei Y1, Zhao Z1, The 6th People’s Hospital of Shanghai, Shanghai, China, 2Peking University, Beijing, China, 3Guanghua School of Management, Peking University, Beijing, China, 4Amgen, Inc., Thousand Oaks, CA, USA, 5Amgen Inc., Thousand Oaks, CA, USA

5:15PM-5:30PM
PG4
DU2
Example of Analysis Utilizing Real World Data: Medical Cost Reduction of Combination Drugs
Iwasaki K1, Kogo N1, Del M1, Milliman Inc., Tokyo, Japan

5:30PM-5:45PM
PG5
DU3
Trends of Hypnotic Medication Use in a 2000-Bed Medical Center in Taiwan
Lin W1, Lin C1, Chang C1, Chou C2, Chao P3, Hsu C4, Chang L1, Hsieh Y1, Hung JS1, Hung W2, Cho D1, 1Medical University, Taichung, Taiwan, 2China Medical University Hospital, Taichung, Taiwan

5:45PM-6:00PM
PG5
DU4
Statin Medication Use and the Development of Proliferative Diabetic Retinopathy Among Patients with Type 2 Diabetes, Hypertension, and Hyperlipidemia
Han Y1, Balkrishnan R1, Thompson DA1, Richards JE1, Stein JD1, University of Michigan, Ann Arbor, MI, USA

Health Services Research Studies Hall SC (Level 1)

Moderator: Vivian WY Lee, PharmD, Associate Professor, The Chinese University of Hong Kong, Hong Kong, China

5:00PM-5:15PM
PG6
HS1
Clinical Outcomes Associated with the Use of Guideline Recommended Care in Patients Post Discharge from Chronic Obstructive Pulmonary Disease (COPD)
Taychakhoonavudh S1, Swint JM1, Chan W1, Franzini L1, 1Chulalongkorn University, Bangkok, Thailand, 2The University of Texas School of Public Health, Houston, TX, USA

5:15PM-5:30PM
PG6
HS2
Medication Adherence as a Value Measure: A Rarity in Evaluation Assessments Submitted to Major HTA Bodies
Singla S1, Amina B1, Nick M2, Outteridge G2, 1Kinapex Ltd., Gurgaon, India, 2Kinapex Ltd., Wimbledon, England

5:30PM-5:45PM
PG7
HS3
Had the Individual Medical Burden of Basic Health Insurance Participants Really Been Alleviated in 2009-2012?
Cui B1, Liu G1, Xiong X2, Li J2, 1Peking University, Beijing, China, 2China Health Insurance Research Association, Beijing, China

5:45PM-6:00PM
PG7
HS4
Qualitative Assessment of the Quality of Pharmaceutical Care Services in the Province of Khyber Pakhtunkhwa, Pakistan: Hospital Pharmacists’ Views
Murtaza Q1, Kouzar R1, Azhur S2, Khan SA1, 1COMSATS, Abbottabad KPK Pakistan, Pakistan, 2COMSATS, Abbottabad, Pakistan, 3COMSATS Institute of Information Technology, Abbottabad, Pakistan

Mental Health Outcomes Research Studies Hall SA (Level 1)

Moderator: Guk-Hee Suh, PhD, MD, Professor of Psychiatry, Hallym University College of Medicine, Dongtan Sacred Heart Hospital, Hwaseong, South Korea

5:00PM-5:15PM
PG7
MH1
Efficacy and Safety of Paliperidone Palmitate in the Treatment of Schizophrenia: A Meta-analysis
Huang Y1, Liu G1, Wang C1, Liu Y1, 1Peking University, Beijing, China, 2Guanghua School of Management, Peking University, Beijing, China, 3Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China

5:15PM-5:30PM
PG8
MH2
Current Impact of Dementia on the Caregiver in China
Yan J1, Clay E1, Aballea S2, Zhai S1, Zhan S1, Toumi M1, 1Creative-CEPTUAL, London, UK, 2Creative-CEPTUAL, Paris, France, 3The Third School of Clinical Medicine, Peking University, Beijing, China, 4Peking University, Beijing, China, 5University of Marseille, Marseille, France

5:30PM-5:45PM
MH3
Factors Associated with Relocating to Nursing Homes among Community-Dwelling Older Persons with Dementia
Rhee Y1, Dongduk Women’s University, Seoul, South Korea

5:45PM-6:00PM
PG9
MH4
Clinical and Economic Outcomes of Memantine Used in Moderate or Severe Dementia Patients in China: Results from a Health Economic Model
Ge L1, Clay E2, Yan J1, Toumi M1, 1Lundbeck China, Beijing, China, 2Creative-CEPTUAL, Paris, France, 3Creative-CEPTUAL, London, UK, 4University of Marseille, Marseille, France, 5Lundbeck Singapore Pte Ltd., Singapore
PHARMACOECONOMICS (PE) GUIDELINES IN ASIA

Christoph Glaetzer, DiplKfm
Vice President, Market Access, Asia-Pacific, Johnson & Johnson, Singapore Ltd., Seoul, South Korea;

Economics, Department of Corporate Affairs and Quality Control, Novo Nordisk China, Beijing, China;

Fengyu Sun, MD, MSc,
Head of Pricing, Health Economics and Reimbursement, Boston Scientific, Singapore;

Moderator: Shanlian Hu, MD, MSc
2014-2016 Chair, ISPOR Asia Consortium Health Technology Assessment Agencies, Health Care Policymakers & Payers (HTA & Policymakers) Committee
Presented by the ISPOR Asia Consortium Health Technology Assessment Agencies, Health Care Policymakers & Payers (HTA & Policymakers) Committee
Hall 2 (Level 2)

ASSESSING HEALTH CARE DELIVERY IN ASIA

Kun Zhao, MD, PhD, MHSc
Professor & Director, Centre of Health Policy Evaluation and Technology Assessment and China National Health Development Centre, National Health and Family Planning Commission, Beijing, China;

Joanne Yoong, PhD
Assistant Professor, National University of Singapore, Singapore

Moderator: Joanne Yoong, PhD
Assistant Professor, National University of Singapore, Singapore
Presented by the ISPOR Asia Consortium Health Service Providers (Clinicians) Committee
Hall 5B (Level 1)
9:45AM-10:45AM WORKSHOPS – SESSION I

CLINICAL OUTCOMES RESEARCH
W1: HOW ROBUST ARE POOLED ESTIMATES FROM META-ANALYSES? Hall 5A (Level 1)
Discussion Leaders: Olivia Wu, PhD, Professor of Health Technology Assessment, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK; Neil S Hawkins, PhD, CStat, Reader in Health Technology Assessment, London School of Hygiene and Tropical Medicine, London, UK; Nathorn Chaiyakunapruk, PhD, PharmD, Professor of Health Economics, Discipline of Pharmacy, Monash University Malaysia, Selangor, Malaysia

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W2: GOING LOCAL – STRATEGY, TECHNIQUES, AND EFFICIENCY IN ASIA-PACIFIC ADAPTATION OF USA AND EU-BASED ECONOMIC MODELS
Chinese=English Interpretation Hall 2 (Level 2)
Discussion Leaders: Rachel Beckerman, PhD, Principal, Value Demonstration, CBPartners, New York, NY, USA; Sandeep Duttagupta, PhD, Principal, CBPartners, New York, NY, USA; Amy Lin, Assistant HEOR Manager, Bayer Taiwan, Taipei, Taiwan; Cyrus A. Chowdhury, MS, Chief Executive Officer, CBPartners, New York, NY, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH
W3: ESTABLISHING NATIONAL EQ-SD-SL PREFERENCE WEIGHTS FOR HEALTH TECHNOLOGY ASSESSMENT Room 201AB (Level 2)
Discussion Leaders: Nan Luo, PhD, Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Min-Woo Jo, PhD, MD, Physician, University of Ulsan, Seoul, South Korea; Juntana Pattanaphesaj, MSc, PhD student, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; Juan Manuel Ramos-Goñi, Msc, Research Scientist, The EuroQol Group Foundation, Rotterdam, The Netherlands

USE OF REAL WORLD DATA
W4: SIMULTANEOUS DEVELOPMENT OF PRO INSTRUMENTS INTENDED FOR GLOBAL USE Hall 5B (Level 1)
Discussion Leaders: Keiko Wada, MA, Senior Research Associate, Adelphi Values, Tokyo, Japan; Selena Daniels, PharmD, MS, Principal Research Associate, Allergan, Inc., Irvine, CA, USA; Rob Arbuckle, MSc, Director, Adelphi Values Ltd., Bollington, UK; Bruce Crawford, MPH, MA, Senior Principal, Real World Evidence Solutions, Japan & APAC, IMS Health KK, Tokyo, Japan

10:45AM-11:15AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Hall 4 (Level 1)
Coffee break sponsored by Analysis Group

11:15AM-12:15PM WELCOME & SECOND PLENARY SESSION Hall 2 (Level 2)
Chinese=English Interpretation

WELCOME
Yen-Huei (Tony) Tarn, MS, PhD, 2014-2016 ISPOR Asia Consortium Executive Committee Chair and Executive Director of Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

ELECTRONIC HEALTH RECORDS FOR INFORMED HEALTH CARE IN ASIA-PACIFIC: LEARNING FROM EACH OTHER
Health care data is essential for evidence-based decision making, but with the current data deficit in Asia, providers, researchers, and policy makers are often limited in how they can better apply the knowledge and make the right decision for the patient. Electronic Health Records (EHRs) are an important resource for capturing patients’ up-to-date health information accurately and completely for smarter health care. This session will focus on issues that the health care systems in Asia are facing in developing EHR software, collecting and using data, as well as privacy concerns. International experience and lessons-learned will be shared and how EHRs can be adopted in Asia will be examined.
Moderator: Jianfei (Jeff) Guo, PhD, RPh, Professor of Pharmacoconomics & Pharmacoepidemiology, Division of Pharmacy Practice & Administrative Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA
Speakers: Daopu Xie, Director, Huangzhou Municipal Medical Insurance Bureau, Zhejiang Province, China; Naoto Kume, PhD, Associate Professor, EHR Research Unit, Department of Social Informatics, Graduate School of Informatics, Kyoto University, Kyoto Prefecture, Japan; Libby Roughead, PhD, Research Professor, Division of Health Sciences, School of Pharmacy and Medical Sciences and Director, the Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia; Judith K. Jones, MD, PhD, Executive Director, DGI, LLC and Primary Editor, B.R.I.D.G.E. TO DATA®, formerly Director, US FDA’s Division of Drug and Biological Experience (now Office of Safety & Epidemiology), Fairfax, VA, USA

12:45PM-3:45PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Hall 4 (Level 1)
ISPOR 6th Asia-Pacific Conference
6-9 September 2014, Beijing International Convention Center, Beijing, China

Program & Schedule of Events: Monday, 8 September Continued

1:15PM-2:15PM  Educational Symposium  Hall 2 (Level 2)
Diabetes in Asia: Perspectives on Innovation Opportunities for Patients, Providers, and Payers
Sponsored by Eli Lilly and Company

2:30PM-3:30PM  Educational Symposium  Hall 2 (Level 2)
Real-world Evidence in Asia-Pacific: Are We Ready? Challenges and Novel Approaches to Generating Evidence in the Absence of Real-world Data
Sponsored by IMS Health

3:45PM-4:45PM  Workshops – Session II
Economic Outcomes Research
W6: Development of Individual Simulation Models for HTA Submission in Asia  Room 201A (Level 2)
Discussion Leaders: Ying Zheng, MS, MHSA, Research Associate, Health Economics and Epidemiology, Evivdra, Bethesda, MD, USA; Roberto Palencia, MA, Global Manager Health Economics & Outcomes Research, Corporate Market Access, Pricing & Outcomes Research, Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany; Thitima Kongnakorn, PhD, Research Scientist, Health Economics and Epidemiology, Evivdra, Bangkok, Thailand; John Cai, PhD, Director, Center for Healthcare Management and Policy, China Europe International Business School, Shanghai, China

Health Care Policy Development Using Outcomes Research
W7: Using Weighted Criteria for Making Decisions on Off-Patent Medicines: Case Studies from China, Thailand, and Vietnam  Room 201B (Level 2)
Discussion Leaders: Shanlian Hu, MD, MSc, 2014-2016 Chair, ISPOR Asia Consortium Health Technology Assessment Agencies and Health Care Policymakers & Payers (HTA & Policymakers) Committee, Professor of Health Economics, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China; Surachat Ngorsuraches, PhD, 2012-2014 Chair, ISPOR Asia Consortium Executive Committee and Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand; Jie Shen, PhD, Head of Market Access, Abbvott, Basel, Switzerland; Diana Brixner, PhD, RPh, Professor & Chair, Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA

W8: Incorporating the Patient Voice in Health Technology Assessment Decision Making: Experiences from the UK and Taiwan  Hall 5A (Level 1)
Discussion Leaders: Olivia Wu, PhD, Professor of Health Technology Assessment, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK; Neil S Hawkins, PhD, CStat, Reader in Health Technology Assessment, London School of Hygiene and Tropical Medicine, London, UK; Yen-Huei (Tony) Tarn, PhD, MS, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

Patient-reported Outcomes & Patient Preference Research
W9: Time Trade-off Procedures for Measuring Health-State Preferences  Hall 5B (Level 1)
Discussion Leaders: Nan Luo, PhD, Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Kim Rand-Hendriksen, PhD, Psychologist, Faculty of Medicine, University of Oslo, Oslo, Norway; Mark Oppe, PhD, Research Scientist, The EuroQol Group Foundation, Rotterdam, The Netherlands; Koonal Shah, PhD, Senior Economist, Office of Health Economics, London, UK

Use of Real World Data
W10: Conducting Outcomes Research Using Electronic Databases in Asia-Pacific  Hall 5C (Level 1)
Discussion Leaders: Chiu-fang Chiou, PhD, Director, Market Access, Janssen Asia Pacific, Singapore; Nathorn Chaiyakunapruk, PhD, PharmD, Professor of Health Economics, Discipline of Pharmacy, Monash University Malaysia, Selangor, Malaysia; Bruce Crawford, MPH, MA, Senior Principal, Real World Evidence Solutions, Japan & APAC, IMS Health KK, Tokyo, Japan

4:45PM-5:00PM  Break, Exhibits & Research Poster Presentations Viewing – Session II  Hall 4 (Level 1)
Coffee break sponsored by Truven Health Analytics

5:00PM-6:00PM  Research Podium Presentations – Session II
(Cardiovascular Disease Outcomes Research Studies  Hall 5B (Level 1)
Moderator: Jian Xie, MD, PhD, Vice President, Analysis Group, Inc., and Beijing Analysis International Consulting Co., Ltd., Beijing, China

Cardiovascular Disease Outcomes Research Studies  Hall 5B (Level 1)
5:00PM-5:15PM  CV1  Comparison of Oral Versus Intravenous NSAIDs for the Treatment of Patent Ductus Arteriosus in Preterm and/or Low Birth Weight Infants: A Systematic Review and Meta-analysis  Chaiyapak R, Surin Hospital, Surin, Thailand

5:15PM-5:30PM  CV2  Management of Ischaemic Stroke Patients Enrolled in the Japan Stroke Database (JSD)  Murteira S, Toumi M, Dorey P, Dabbous FM, Kobayashi S, Lundbeck Japan KK, Tokyo, Japan, 1University Claude Bernard Lyon 1, Lyon, France, 2Institut Jean-Rostand, University of Illinois at Chicago, Chicago, IL, USA, 1University of Illinois at Chicago, Chicago, IL, USA, 1Shimane University, Matsue-shi, Japan

5:30PM-5:45PM  CV3  Economic Evaluation of Change in Reimbursement Criteria for Lipid-lowering Drugs in Taiwan  Wu GH, Wang Y, Pwu R, 1Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, and Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei, Taiwan, 2Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, Taipei, Taiwan

Page numbers to the left refer to the abstract location in the ISPOR 6th Asia-Pacific Conference Research Abstracts PDF, available online at www.ispor.org and in the new meeting app.

Program & Schedule of Events: Monday, 8 September Continued

1:15PM-2:15PM  Educational Symposium  Hall 2 (Level 2)
Diabetes in Asia: Perspectives on Innovation Opportunities for Patients, Providers, and Payers
Sponsored by Eli Lilly and Company

2:30PM-3:30PM  Educational Symposium  Hall 2 (Level 2)
Real-world Evidence in Asia-Pacific: Are We Ready? Challenges and Novel Approaches to Generating Evidence in the Absence of Real-world Data
Sponsored by IMS Health

3:45PM-4:45PM  Workshops – Session II
Economic Outcomes Research
W6: Development of Individual Simulation Models for HTA Submission in Asia  Room 201A (Level 2)
Discussion Leaders: Ying Zheng, MS, MHSA, Research Associate, Health Economics and Epidemiology, Evivdra, Bethesda, MD, USA; Roberto Palencia, MA, Global Manager Health Economics & Outcomes Research, Corporate Market Access, Pricing & Outcomes Research, Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany; Thitima Kongnakorn, PhD, Research Scientist, Health Economics and Epidemiology, Evivdra, Bangkok, Thailand; John Cai, PhD, Director, Center for Healthcare Management and Policy, China Europe International Business School, Shanghai, China

Health Care Policy Development Using Outcomes Research
W7: Using Weighted Criteria for Making Decisions on Off-Patent Medicines: Case Studies from China, Thailand, and Vietnam  Room 201B (Level 2)
Discussion Leaders: Shanlian Hu, MD, MSc, 2014-2016 Chair, ISPOR Asia Consortium Health Technology Assessment Agencies and Health Care Policymakers & Payers (HTA & Policymakers) Committee, Professor of Health Economics, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China; Surachat Ngorsuraches, PhD, 2012-2014 Chair, ISPOR Asia Consortium Executive Committee and Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand; Jie Shen, PhD, Head of Market Access, Abbvott, Basel, Switzerland; Diana Brixner, PhD, RPh, Professor & Chair, Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA

W8: Incorporating the Patient Voice in Health Technology Assessment Decision Making: Experiences from the UK and Taiwan  Hall 5A (Level 1)
Discussion Leaders: Olivia Wu, PhD, Professor of Health Technology Assessment, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK; Neil S Hawkins, PhD, CStat, Reader in Health Technology Assessment, London School of Hygiene and Tropical Medicine, London, UK; Yen-Huei (Tony) Tarn, PhD, MS, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

Patient-reported Outcomes & Patient Preference Research
W9: Time Trade-off Procedures for Measuring Health-state Preferences  Hall 5B (Level 1)
Discussion Leaders: Nan Luo, PhD, Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Kim Rand-Hendriksen, PhD, Psychologist, Faculty of Medicine, University of Oslo, Oslo, Norway; Mark Oppe, PhD, Research Scientist, The EuroQol Group Foundation, Rotterdam, The Netherlands; Koonal Shah, PhD, Senior Economist, Office of Health Economics, London, UK

Use of Real World Data
W10: Conducting Outcomes Research Using Electronic Databases in Asia-Pacific  Hall 5C (Level 1)
Discussion Leaders: Chiu-fang Chiou, PhD, Director, Market Access, Janssen Asia Pacific, Singapore; Nathorn Chaiyakunapruk, PhD, PharmD, Professor of Health Economics, Discipline of Pharmacy, Monash University Malaysia, Selangor, Malaysia; Bruce Crawford, MPH, MA, Senior Principal, Real World Evidence Solutions, Japan & APAC, IMS Health KK, Tokyo, Japan

4:45PM-5:00PM  Break, Exhibits & Research Poster Presentations Viewing – Session II  Hall 4 (Level 1)
Coffee break sponsored by Truven Health Analytics

5:00PM-6:00PM  Research Podium Presentations – Session II
(Cardiovascular Disease Outcomes Research Studies  Hall 5B (Level 1)
Moderator: Jian Xie, MD, PhD, Vice President, Analysis Group, Inc., and Beijing Analysis International Consulting Co., Ltd., Beijing, China

Cardiovascular Disease Outcomes Research Studies  Hall 5B (Level 1)
5:00PM-5:15PM  CV1  Comparison of Oral Versus Intravenous NSAIDs for the Treatment of Patent Ductus Arteriosus in Preterm and/or Low Birth Weight Infants: A Systematic Review and Meta-analysis  Chaiyapak R, Surin Hospital, Surin, Thailand

5:15PM-5:30PM  CV2  Management of Ischaemic Stroke Patients Enrolled in the Japan Stroke Database (JSD)  Murteira S, Toumi M, Dorey P, Dabbous FM, Kobayashi S, Lundbeck Japan KK, Tokyo, Japan, 1University Claude Bernard Lyon 1, Lyon, France, 2Institut Jean-Rostand, University of Illinois at Chicago, Chicago, IL, USA, 1University of Illinois at Chicago, Chicago, IL, USA, 1Shimane University, Matsue-shi, Japan

5:30PM-5:45PM  CV3  Economic Evaluation of Change in Reimbursement Criteria for Lipid-lowering Drugs in Taiwan  Wu GH, Wang Y, Pwu R, 1Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, and Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei, Taiwan, 2Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, Taipei, Taiwan

(Page numbers to the left refer to the abstract location in the ISPOR 6th Asia-Pacific Conference Research Abstracts PDF, available online at www.ispor.org and in the new meeting app.)
ISPOR 6th Asia-Pacific Conference
6-9 September 2014, Beijing International Convention Center, Beijing, China

Program & Schedule of Events: Monday, 8 September Continued

Health Care Reimbursement Studies: Hall SCD (Level 1)
Moderator: Manny Papadimitriou, PhD, Director, Health Technology Assessment, Emerging Markets, Eli Lilly & Company, Toronto, ON, Canada

5:00PM-5:15PM
HC1 Impact Evaluation of Provider Payment Reform Under the New Rural Cooperative Medical Scheme in Gansu Province, China
Wang X, Su L, The Chinese University of Hong Kong, Hong Kong, China

5:15PM-5:30PM
HC2 Health Care Utilization and Cost Comparison Between Adherent Hypertension Patients Treated by Single Exforge HCT and Amlopidine/Valsartan/Hydrochlorothiazide Free Combination
Chen W, Wei Z, Ong SH, Machnicki G, Kristijan K, Beijing Novartis Pharma Co. Ltd., Shanghai, China, Novartis Pharma AG, Basel, Switzerland, Novartis Argentina SA, Buenos Aires, Argentina, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

5:30PM-5:45PM
HC3 Anticipated Price Disclosure: Impact on Funding Decisions in Australia
Harrison JP, Cook G, Kim H, Bristol-Myers Squibb, Melbourne, Australia

5:45PM-6:00PM
HC4 Why Does Anti-Infective Drug Expenditure Increase? A Decomposition Analysis on China Data
Liu X, Wu J, Yue N, Tianjin University, Tianjin, China

Infectious Disease Outcomes Research Studies: Room 201A (Level 2)
Moderator: Alex Z. Fu, PhD, Associate Professor, Cancer Prevention and Control Program, Georgetown University Medical Center, Washington, DC, USA

5:00PM-5:15PM
IN1 Comparative Safety and Efficacy of Focused Ultrasound for Cervical Ectopy: A Meta Analyses with 16180 Patients
Tang X, Yu J, Li Y, Li X, West China Hospital, Sichuan University, Chengdu, China

5:15PM-5:30PM
IN2 Effect of Vaccination Age on Cost-Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer in China
Liu Y, Zhang Q, Hu S, Zhao F, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

5:30PM-5:45PM
IN3 Cost-Effectiveness Analysis of Caspofungin Compared to Conventional Amphotericin B (C-AMB) for Empirical Antifungal Therapy in Febrile Neutropenic Patients in Thailand
Chayakulkeeree M, Numuang K, Lerdlitruangsri S, Itzler R, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, formerly of MSD (Thailand) Ltd., Bangkok, Thailand, formerly of MSD (Thailand) Ltd., Bangkok, Thailand, formerly of Merck Sharp & Dohme Corp, North Wales, PA, USA

5:45PM-6:00PM
IN4 Impact of Maternal Education on Child Immunization Propensity in China
Ding Y, Hai J, University of Southern California, Los Angeles, CA, USA

Qaly-Related Studies: Hall SA (Level 1)
Moderator: Bruce Crawford, MA, MPH, Senior Principal, Real World Evidence Solutions, Japan & APAC, IMS Health KK, Tokyo, Japan

5:00PM-5:15PM
QA1 Comparison of the Preference-Based EQ-5D and SF-6D Health Indices in Multiethnic Asian Patients with End-Stage Renal Disease (ESRD)
Yangs J, Lau TJ, Lee E, Vathsala A, Chia KS, Luo N, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Division of Nephrology, University Medicine Cluster, National University Health System, Singapore

5:15PM-5:30PM
QA2 An Analysis of New Health Technologies and Reimbursement Pricing Structures in Taiwan
Stewart G, Brooks-Rooney C, Costello Medical Consulting Ltd., Cambridge, UK, Costello Medical Singapore Pte Ltd., Singapore

5:30PM-5:45PM
QA3 Cost-Effectiveness of Thrombolysis Within 4.5 Hours of Acute Ischemic Stroke in China
Pan Y, Wang Y, Liu G, Zhao K, Wang Y, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, National Health and Family Planning Commission, Beijing, China

5:45PM-6:00PM
QA4 Cost-Utility of Bevacizumab with PC Regimen in Non-Small Cell Lung Cancer Treatment
Nguyen TT, Tran TT, University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam

Respiratory-Related Disorders Outcomes Research Studies: Room 201B (Level 2)
Moderator: Xin Sun, PhD, Professor, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China

5:00PM-5:15PM
RR1 Asthma Guideline Knowledge, Adherence, and Cost of Treating Asthma at Emergency Department
Khan AH, Syed Sulaiman A, Hassali AA, Saleem F, Afzal RA, Ali J, University Sains Malaysia, Minden, Malaysia, University Sains Malaysia, Penang, Malaysia, Universiti Sains Malaysia, Penang, Malaysia, Penang General Hospital, Penang, P. Pinang, Malaysia

5:15PM-5:30PM
RR2 Resource Utilization Pattern and Cost of Tuberculosis Treatment in Penang, Malaysia
Atif M, Sulaiman SA, Shaifie AA, Asif M, The Islamia University of Bahauwalpur, Bahauwalpur, Pakistan, Universiti Sains Malaysia, Penang, Malaysia

5:30PM-5:45PM
RR3 Awareness and Prevention of Chronic Diseases in Japan
Gupta S, Fukuda T, Stankus AP, Kanter Health, Princeton, NJ USA, National Institute of Public Health, Saitama, Japan

5:45PM-6:00PM
RR4 Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies in Korea
Park DJ, Kim YH, Kim EJ, Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea, Seoul National University, Seoul, South Korea, Graduate School of Public Health, Seoul National University, Seoul, South Korea
TUESDAY, 9 SEPTEMBER

7:15AM-8:15AM  EDUCATIONAL SYMPOSIUM  Hall 5CD (Level 1)
THE ROLE OF HTA IN HEALTH CARE DECISION MAKING
Sponsored by MSD

8:30AM-2:15PM  RESEARCH POSTER PRESENTATIONS – SESSION III  Hall 4 (Level 1)

8:30AM-9:30AM  WORKSHOPS – SESSION III

ECONOMIC OUTCOMES RESEARCH
W11: EXPECTED VALUE OF PERFECT INFORMATION: ACTIVE LEARNING THROUGH USER-FRIENDLY COMPUTATIONS, DISPLAYS, AND ASIA-PACIFIC APPLICATION DISCUSSIONS  Hall 5A (Level 1)
Discussion Leaders: Jonathan D Campbell, PhD, Assistant Professor, School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; R. Brett McQueen, PhD, Post Doctoral Fellow, School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Jonathan H. Watanabe, PharmD, MS, PhD, Assistant Professor, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA; Nathan Chaiyakunapruk, PhD, PharmD, Professor of Health Economics, Discipline of Pharmacy, Monash University Malaysia, Selangor, Malaysia

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W12: MAXIMIZING ACCESS OF INNOVATIVE DRUGS IN CHINA  Room 201A (Level 2)
Discussion Leaders: Chris Smith, PhD, Professor, Center for Pharmacoeconomic Research and Evaluation, School of Public Health, Fudan University, Shanghai, China; Xin (Cindy) Gao, PhD, Professor, Clinical Research and Evaluation Unit, Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; Wei Zhou, PhD, Professor, Department of Health Economics, School of Public Health, Sun Yat-Sen University, Guangzhou, China; Kejun Liu, PhD, Senior Director, Merck Research Laboratories, Beijing, China; Hengjin Dong, MD, PhD, Senior Health Economics & Outcomes Research Advisor, Pfizer Investment Co. Ltd., Beijing, China; Yi Han, PhD, Senior Vice President, Market Access and HEOR, WGI, Ewha Womans University, Seoul, South Korea; Chuan Yu, PhD, Director, Redwood Outcomes, Vancouver, BC, Canada; Nathan Chaiyakunapruk, PhD, PharmD, Professor of Health Economics, Discipline of Pharmacy, Monash University Malaysia, Selangor, Malaysia

USE OF REAL WORLD DATA
W14: CHALLENGES AND STRATEGIES OF OUTCOME RESEARCH USING LARGE ELECTRONIC MEDICAL RECORDS DATABASES IN THE CHINESE SETTING  Hall 5B (Level 1)
Discussion Leaders: Xin Sun, PhD, Director, Clinical Research and Evaluation Unit, Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; Wei Zhou, PhD, Director, Scientific Staff, Emeriti Research Laboratories, Merck Research Laboratories, Beijing, China; Shuyu Li, MD, Physician, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China; Chuan Yu, PhD, Research Associate, Clinical Research and Evaluation Unit, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China

W15: IMPROVING THE VALIDITY OF HEALTH ECONOMIC RESEARCH USING BIG DATA AND REAL-WORLD EVIDENCE  Hall 5CD (Level 1)
Discussion Leaders: Wen Chen, PhD, Professor, Center for Pharmaco-economic Research and Evaluation, School of Public Health, Fudan University, Shanghai, China; Jianwei Xuan, MD, PhD, Assistant Professor, School of Public Health, Sun Yat-Sen University, Guangzhou, China; Yi Han, PhD, Senior Vice President, Market Access and HEOR, WGI, Ewha Womans University, Seoul, South Korea; Kejun Liu, PhD, Senior Director, Redwood Outcomes, Vancouver, BC, Canada; Beijing, China; Chuan Yu, PhD, Director, Redwood Outcomes, Vancouver, BC, Canada; Nathan Chaiyakunapruk, PhD, PharmD, Professor of Health Economics, Discipline of Pharmacy, Monash University Malaysia, Selangor, Malaysia

9:45AM-10:45AM  ISSUE PANELS – SESSION II

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP6: UPDATING REIMBURSEMENT GUIDELINES IN ASIA-PACIFIC: WHO’S DOING WHAT?  Hall 5A (Level 1)
Moderator: Danny Liev, FRACP, PhD, Professor, Medicine (RMH), The University of Melbourne, Melbourne, Australia
Panelists: Lloyd Sansom AO, PHC, PhD, Adel, FPS, Emeritus Professor, School of Pharmacy and Medical Sciences, University of South Adelaide, Adelaide, Australia; Seungjin Bae, ScD, RPh, Assistant Professor, College of Pharmacy, Ewha Womans University, Seoul, South Korea; Greg Cook, PhD, Associate Director, Bristol-Myers Squibb, Melbourne, Australia

IP7: IS THE PRICE LEVEL IN HTA COUNTRIES REFLECTED IN THE REWARD FOR INNOVATION?  Room 201B (Level 2)
Moderator: Eui-Kyung Lee, PhD, Professor & Researcher, School of Pharmacy, Sungkyunkwan University, Suwon, Korea
Panelists: Donald Yin, PhD, 2014-2016 Chair, ISPOR Asia Consortium Health Technology Producers (Industry) Committee and Associate Vice President & Head, Global Health Outcomes, Merck & Co. Inc., Whitehouse Station, NJ, USA; Gordon Liu, PhD, Professor of Economics, National School of Development (NSD) and Director, China Center for Health Economic Research (CCHER), Peking University, Beijing, China; Jinikim Kim, Manager, National Health Insurance Service, Seoul, South Korea
ISPOR 6th Asia-Pacific Conference
6-9 September 2014, Beijing International Convention Center, Beijing, China

Program & Schedule of Events: Tuesday, 9 September Continued

IP8: HTA, Budget Impact Tools, and International Price Referencing From China’s Perspective: What Are the Current Developments and Future Considerations? Hall 5CD (Level 1)
Moderator: Liling Koh, PhD, BEng (1st Hons). Associate Director, Market Access, Asia-Pacific, Johnson & Johnson, Singapore
Panelists: Shu Chuen Li, PhD, MBA, MSc, Professor, Chair & Head, School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia; Meng Zhang, MBA, MSc, Senior Principal, Pricing and Market Access, Asia-Pacific, IMS Consulting, Shanghai, China; Christoph Glaetzer, DiplKfm, Vice President, Market Access, Asia-Pacific, Johnson & Johnson, Singapore

Patient-reported Outcomes & Patient Preference Research Issues
IP9: Does Involving Patients in Evolving HTA Processes in Asia-Pacific Help or Hurt Decision Making? Room 201A (Level 2)
Moderator: Yen-Huei (Tony) Tarn, MS, PhD, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan
Panelists: Xiao Zhang, MD PhD, Director, Health Insurance, Public School, Southeast University, Nanjing, China; Durhane Wong-Rieger, PhD, President & CEO, Institute for Optimizing Health Outcomes, Toronto, ON, Canada; Grace Hui-Min Wu, PhD, Researcher, Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, and Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei, Taiwan

Use of Real World Data Issues
IP10: Informing Treatment Paradigms: What Are the Approaches to Data Collection in Asia-Pacific Countries? Hall 5B (Level 1)
Moderator: Beth A O’Leary, MAACB, MPH, Associate Executive Director, Health Economics, Covance Pte Ltd., North Ryde, Australia
Panelists: Andrew J Palmer, MBBS, Professor, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia; Kristy Hardy, MPH, Senior Manager, Health Economics and Market Access, Johnson & Johnson Medical, Sydney, Australia; Heather J McElroy, MMedStat, Director, Health Economics, Covance (Asia) Pte Ltd., Singapore

10:45AM-11:45AM Research Poster Author Discussion Hour – Session III Hall 4 (Level 1)

11:15AM-2:15PM Lunch, Exhibits & Research Poster Presentations Viewing – Session III Hall 4 (Level 1)

11:45AM-12:45PM Educational Symposium Hall 5CD (Level 1)
Technology Empowered Health Care: Friend or Foe?
Sponsored by Double Helix Consulting

1:00PM-2:00PM Educational Symposium Hall 5CD (Level 1)
Health, Access, and Economic Prosperity
Sponsored by RDPAC

2:15PM-3:15PM Workshops – Session IV

Clinical outcomes Research
W16: Dynamic Network Evaluations: Staying Up-to-Date with Decision Making Room 201A (Level 2)
Discussion Leaders: Kristian Thorlund, PhD, MStat, Director, Redwood Outcomes, Vancouver, BC, Canada; Ping Wu, MBBS, Associate Scientist, Shanghai Jiaotong University, Shanghai, China; Edward J Mills, PhD, Associate Professor, Stanford University, Stanford, CA, USA

Economic outcomes Research
W17: The German Efficiency Frontier Approach for Economic Evaluation and Applicability in Asia Chinese=English Interpretation Hall 2 (Level 2)
Discussion Leaders: Isao Kamae, MD, DrPH, Professor, Health Technology Assessment and Public Policy, The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan; J. Jaime Caro, MD, CM, FRCP, FACP, Chief Scientist, Evidera, Lexington, MA, USA; Frank Gerd Sandmann, MSc, Research Associate, Health Economics, Institute for Quality and Efficiency in Health Care (IQWiG), Köl, Germany

Health Care Policy Development Using Outcomes Research
W18: Irrational Exuberance: Can HTA Ever Incentivize Innovation? Case Studies from Korea and Taiwan Hall 5A (Level 1)
Discussion Leaders: Sandeep Duttagupta, PhD, Principal, CBPartners, New York, NY, USA; Cyrus A. Chowdhury, MPH, Chief Executive Officer, CBPartners, New York, NY, USA; Amy Lin, Assistant HEOR Manager, Bayer Taiwan, Taipei, Taiwan; Su-Kyoung Ko, PhD, Market Access Director, Health & Value, Pfizer Pharmaceuticals Korea Limited, Seoul, South Korea

Use of Real World Data
W19: Real World Data Generation Using Health Care Databases in Japan Hall 5B (Level 1)
Discussion Leaders: Aya Narimatsu, MPH, Project Leader, Health Economics and Outcomes Research, Japan, Bayer Yakuhin, Ltd., Tokyo, Japan; Koji Kawakami, MD, PhD, Professor, Department of Pharmacoeconomics, Graduate School of Medicine and Public Health, Kyotou University, Kyoto, Japan; Shinya Matsuda, MD, PhD, Professor, Department of Preventive Medicine and Community Health, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Fukuoka, Japan; Yoshiki Ishikawa, PhD, MS, Innovation Director, Cancer Scan Inc., Tokyo, Japan

W20: Value of Real World Non-Interventional Research in Oncology: Global and Asia Experiences and Challenges Hall 5CD (Level 1)
Discussion Leaders: Peter Feng Wang, MD, PhD, Director, Priority Markets, Global Health Economics and Outcomes Research, Bristol-Myers Squibb, Lawrenceville, NJ, USA; Yingyao Chen, PhD, Professor, Deputy Director, National Key Lab of Health Technology Assessment, Fudan University, Shanghai, China; Zhiliu Tang, PhD, Head of HEOR, Bristol-Myers Squibb, Shanghai, China; Grace-Shulan He, MD, Director/DAH for Oncology in Medical Affairs, Bristol-Myers Squibb, China, Shanghai, China
3:15PM-3:30PM  
**BREAK**  
**Hall 4 Foyer (Level 1)**

3:30PM-5:00PM  
**WELCOME & THIRD PLENARY SESSION**  
**Hall 2 (Level 2)**  

*Chinese=English Interpretation*

**WELCOME**

Yen-Huei (Tony) Tarn, MS, PhD, 2014-2016 ISPOR Asia Consortium Executive Committee Chair and Executive Director of Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

---

**CHINA HEALTH CARE REFORM: WHO GAINS AND WHO LOSES?**

Health care reform, launched in 2009, has brought significant changes to the health care system and infrastructure in China, and has created new opportunities for different stakeholders. As reform has been implemented in the past decade, the question has become, "Who are the true winners and who are the losers? Is the reform successful in achieving its goal of equality and quality of care for all patients?" During this session, experiences and lessons learned with South Korea’s successful health care reform, USA’s Affordable Health Care Act (Obamacare), as well health care reform in China will be debated. The trend of China health care reform for the next decade will also be explored.

**Moderator:** Isao Kamae, MD, DrPH, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, University of Tokyo, Tokyo, Japan

**Speakers:**
- Gordon G. Liu, PhD, Professor of Economics, National School of Development (NSD), and Director, China Center for Health Economic Research (CCHER), Peking University, Beijing, China
- Soonman Kwon, PhD, Professor of Health Economics and Policy in the Program of Health Care Management and Policy and Former Dean of Graduate School of Public Health, Seoul National University, Seoul, South Korea
- Joel Hay, PhD, MS, MPhil, Professor of Pharmaceutical Economics & Policy, USC Schaeffer Center, University of Southern California, Calabasas, CA, USA
- Bernhard Schwartländer, PhD, World Health Organization Chief Representative in China, Beijing, China

5:00PM-5:30PM  
**ISPOR SERVICE & RESEARCH AWARDS PRESENTATION, ISPOR 7TH ASIA-PACIFIC CONFERENCE ANNOUNCEMENT & CLOSING REMARKS & RECEPTION**  
**Hall 2 (Level 2)**

*Chinese=English Interpretation*

**Moderated by:** Yen-Huei (Tony) Tarn, MS, PhD, Executive Director of Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

**ISPOR DISTINGUISHED SERVICE AWARDS PRESENTATION**

*Presented by:* Adrian Towse, MA, MPhil, 2014-2015 ISPOR President and Director, Office of Health Economics, London, UK

**AWARDEES:**
- Guowei Sang, ISPOR 6th Asia-Pacific Conference Honorary Chair, President of Chinese Pharmaceutical Association (CPA), Academician of Chinese Academy of Engineering (CAE), and Vice Chairman of the Standing Committee of the 11th National People’s Congress, Beijing, China
- Gordon G. Liu, PhD, ISPOR 6th Asia-Pacific Conference Program Chair, Professor of Economics, National School of Development (NSD), and Director, China Center for Health Economic Research (CCHER), Peking University, Beijing, China
- Surachat Ngorsuraches, PhD, 2012-2014 ISPOR Asia Consortium Executive Committee Chair and Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand
- Jie Chen, PhD, 2012-2014 Chair, ISPOR Asia Consortium HTA Agencies, Policymakers & Payers Committee, Director, WHO Collaborating Centre for HTA & M, Director, Center for Health Technology Assessment, Shanghai Municipal Bureau, and Professor, School of Public Health, Fudan University, Shanghai, China

**ISPOR RESEARCH AWARDS PRESENTATION**

*Presented by:* Guowei Sang, President of Chinese Pharmaceutical Association (CPA), Academician of Chinese Academy of Engineering (CAE), and Vice Chairman of the Standing Committee of the 11th National People’s Congress, Beijing, China

**ANNOUNCEMENT OF ISPOR 7TH ASIA-PACIFIC CONFERENCE**

Yen-Huei (Tony) Tarn, MS, PhD, 2014-2016 ISPOR Asia Consortium Executive Committee Chair and Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

**Nan Luo, PhD, ISPOR Singapore Chapter President and Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore**

**CLOSING REMARKS**

Gordon G. Liu, PhD, Professor of Economics, National School of Development (NSD) and Director, China Center for Health Economic Research (CCHER), Peking University, Beijing, China